Compare MORN & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MORN | ABVX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.6B |
| IPO Year | 2004 | 2022 |
| Metric | MORN | ABVX |
|---|---|---|
| Price | $223.60 | $87.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $239.00 | $163.58 |
| AVG Volume (30 Days) | 207.4K | ★ 1.2M |
| Earning Date | 10-28-2026 | 09-21-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 3.38 | N/A |
| EPS | ★ 5.55 | N/A |
| Revenue | ★ $2,445,500,000.00 | N/A |
| Revenue This Year | $8.54 | N/A |
| Revenue Next Year | $5.78 | $1,695.54 |
| P/E Ratio | $40.12 | ★ N/A |
| Revenue Growth | ★ 7.49 | N/A |
| 52 Week Low | $141.49 | $69.81 |
| 52 Week High | $226.07 | $148.83 |
| Indicator | MORN | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 71.13 | 40.02 |
| Support Level | $186.94 | $84.11 |
| Resistance Level | N/A | $128.68 |
| Average True Range (ATR) | 5.48 | 3.93 |
| MACD | 2.71 | 1.00 |
| Stochastic Oscillator | 94.78 | 30.94 |
Morningstar Inc is a provider of independent investment insights to financial advisers, asset managers, and investors. It provides data and research insights on various investment offerings, including managed investment products, publicly listed companies, private capital markets, debt securities, and real-time market data. The company has five reportable segments: Morningstar Direct Platform, PitchBook, Morningstar Credit, Morningstar Wealth, and Morningstar Retirement. Maximum revenue is derived from the Morningstar Direct Platform, which provides investors with comprehensive data, research, insights, and investment analysis through product areas such as Morningstar Data, Morningstar Direct, and Morningstar Advisor Workstation. Geographically, it generates maximum revenue from the USA.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.